THMO - ThermoGenesis Holdings Inc Stock Price, Fair Value and News

0.70USD-0.14 (-16.67%)Market Closed

Market Summary

USD0.70-0.14

Market Closed

-16.67%

THMO Stock Price

View Fullscreen

THMO RSI Chart

THMO Valuation

Market Cap

5.6M

Price/Earnings (Trailing)

-0.29

Price/Sales (Trailing)

0.59

EV/EBITDA

-0.77

Price/Free Cashflow

-1.02

THMO Price/Sales (Trailing)

THMO Profitability

Operating Margin

18.41%

EBT Margin

-176.03%

Return on Equity

527.87%

Return on Assets

-168.44%

Free Cashflow Yield

-97.97%

THMO Fundamentals

THMO Revenue

Revenue (TTM)

9.4M

Rev. Growth (Yr)

-10.09%

Rev. Growth (Qtr)

9.66%

THMO Earnings

Earnings (TTM)

-18.9M

Earnings Growth (Yr)

-112.71%

Earnings Growth (Qtr)

-103.18%

Breaking Down THMO Revenue

Last 7 days

-15.7%

Last 30 days

-7.9%

Last 90 days

75%

Trailing 12 Months

-75.1%

How does THMO drawdown profile look like?

THMO Financial Health

Current Ratio

0.44

Debt/Equity

-0.18

Debt/Cashflow

-5.7

THMO Investor Care

Shares Dilution (1Y)

417.80%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	10.4M	9.6M	9.7M	9.4M
2022	10.4M	11.3M	10.2M	10.5M
2021	8.1M	8.0M	8.8M	9.3M
2020	13.3M	11.2M	9.5M	9.7M
2019	10.8M	13.1M	14.0M	13.0M
2018	11.4M	9.9M	9.9M	9.7M
2017	14.0M	14.5M	13.8M	12.8M
2016	12.7M	11.9M	12.9M	13.6M
2015	16.2M	16.0M	15.2M	13.9M
2014	16.3M	16.0M	16.0M	16.2M
2013	18.3M	18.0M	17.5M	17.2M
2012	19.9M	19.0M	18.3M	18.3M
2011	23.3M	23.4M	21.3M	20.2M
2010	0	23.1M	23.2M	23.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ThermoGenesis Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	xu xiaochun	acquired	1,563,000	0.38	4,113,160	ceo
Nov 17, 2023	xu xiaochun	sold	-612,000	1.02	-600,000	ceo
Sep 28, 2023	xu xiaochun	acquired	700,000	1.07	654,206	ceo
Jun 28, 2022	xu xiaochun	acquired	2,999,990	0.2843	10,552,200	ceo
Apr 28, 2020	xu xiaochun	sold	-1,118,950	1.8	-621,637	ceo
Feb 13, 2020	xu xiaochun	acquired	3,000,010	1.8	1,666,670	ceo
Dec 26, 2019	xu xiaochun	sold	-1,557,160,000,000	2,277,130	-683,824	ceo
Dec 26, 2019	xu xiaochun	bought	1,557,160,000,000	2,277,130	683,824	ceo

Which funds bought or sold THMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-27,591	21,287	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-	1.00	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	new	-	14,289	14,289	-%
Feb 14, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	12,638	12,638	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	152	421	4,636	-%
Feb 13, 2024	MORGAN STANLEY	unchanged	-	-7,240	5,586	-%
Feb 13, 2024	FMR LLC	unchanged	-	-	1.00	-%
Feb 13, 2024	Qube Research & Technologies Ltd	unchanged	-	-3.00	2.00	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-1,162	898	-%

Are Funds Buying or Selling THMO?

Are funds buying THMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own THMO

No. of Funds

Unveiling ThermoGenesis Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 28, 2023	boyalife group, inc.	73%	7,535,821	SC 13D/A
Aug 14, 2023	boyalife group, inc.	77.68%	7,685,483	SC 13D/A
Apr 11, 2023	boyalife group, inc.	75.4%	3,042,693	SC 13D/A
Mar 09, 2023	xu xiaochun	78.3%	2,756,537	SC 13D/A
Feb 16, 2023	foley & lardner/ fa	78.3%	2,756,537	SC 13D/A
Nov 09, 2022	boyalife group, inc.	67.84%	70,984,962	SC 13D/A
Jul 12, 2022	boyalife asset holding ii, inc.	0%	0	SC 13D/A
Feb 11, 2021	renaissance technologies llc	0.00%	0	SC 13G/A
May 21, 2020	ylj yihai ltd	9.98%	621,637	SC 13D
Apr 06, 2020	armistice capital, llc	0%	0	SC 13G

Recent SEC filings of ThermoGenesis Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	10-K	Annual Report
Apr 02, 2024	NT 10-K	NT 10-K
Mar 20, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading
Mar 12, 2024	8-K	Current Report
Jan 10, 2024	8-K	Current Report
Jan 10, 2024	8-K	Current Report

Peers (Alternatives to ThermoGenesis Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

ThermoGenesis Holdings Inc News

Latest updates

ThermoGenesis Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.7%	2,406,000	2,194,000	2,273,000	2,572,000	2,676,000	2,115,000	3,029,000	2,663,000	2,418,000	3,158,000	2,201,000	1,517,000	1,947,000	2,355,000	2,242,000	3,200,000	1,722,000	4,058,000	4,305,000	2,962,000	2,688,000
Gross Profit	-109.6%	-38,000	395,000	469,000	1,105,000	394,000	437,000	939,000	940,000	684,000	1,115,000	986,000	708,000	888,000	1,511,000	-2,632,000	1,492,000	591,500	1,895,000	1,951,000	1,258,000	823,000
Operating Expenses	117.2%	4,240,000	1,952,000	2,199,000	2,150,000	1,921,000	2,452,000	2,381,000	2,149,000	2,009,000	2,220,000	4,124,000	2,371,000	2,303,500	2,594,000	2,556,000	2,701,000	3,827,000	2,225,000	2,213,000	2,164,000	8,672,000
S&GA Expenses	11.2%	1,875,000	1,686,000	1,816,000	1,844,000	1,579,500	1,982,000	1,989,000	1,693,000	1,344,000	1,677,000	3,502,000	1,992,000	1,763,500	1,844,000	1,978,000	2,092,000	429,000	502,000	384,000	341,000	311,000
R&D Expenses	23.7%	329,000	266,000	383,000	306,000	341,500	470,000	392,000	456,000	665,000	543,000	622,000	379,000	540,000	750,000	578,000	609,000	638,000	584,000	611,000	563,000	452,000
EBITDA Margin	17.8%	-0.58	-0.70	-0.79	-0.66	-0.96	-1.05	-0.95	-1.02	-1.06	-0.91	-1.00	-0.99	-	-	-	-	-	-	-	-	-
Interest Expenses	57.8%	3,343,000	2,118,000	668,000	3,903,000	2,043,500	1,391,000	1,359,000	823,000	1,530,000	1,530,000	1,524,000	1,519,000	1,531,500	1,531,000	1,314,000	3,531,000	948,000	1,188,000	1,211,000	1,132,000	768,500
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,279,000
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4,204,000	-2,373,000	-1,475,000	-	-8,574,000
EBT Margin	-2.9%	-1.76	-1.71	-1.73	-1.60	-1.59	-1.63	-1.48	-1.59	-1.79	-1.88	-2.07	-2.06	-	-	-	-	-	-	-	-	-
Net Income	-103.2%	-7,599,000	-3,740,000	-2,398,000	-5,182,000	-3,572,500	-3,403,000	-2,801,000	-2,036,000	-2,885,500	-1,792,000	-4,672,000	-2,531,000	-2,949,000	-2,609,000	-6,510,000	-4,743,000	-4,204,000	-2,373,000	-1,475,000	-2,047,000	-7,295,000
Net Income Margin	-30.7%	-2.00	-1.53	-1.51	-1.44	-1.13	-1.09	-0.84	-1.09	-1.28	-1.35	-1.59	-1.81	-	-	-	-	-	-	-	-	-
Free Cashflow	-418.6%	-2,235,000	-431,000	-1,402,000	-1,386,000	-1,274,000	-1,089,000	-1,096,000	-4,224,000	-355,000	-1,034,000	-1,345,000	-3,979,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-29.5%	11,232	15,921	17,608	19,751	19,386	20,093	21,327	18,279	20,652	22,773	22,403	23,591	20,860	17,289	19,353	18,404	15,214	17,591	16,532	15,630	14,611
Current Assets	-25.2%	5,180	6,925	8,452	10,969	10,884	11,483	12,484	13,194	14,964	16,881	16,077	16,904	15,298	12,776	14,664	13,395	9,521	11,126	9,855	8,853	8,626
Cash Equivalents	-50.2%	2,000	4,018	4,450	5,854	4,177	3,903	4,001	3,652	7,280	7,634	8,668	10,014	7,161	4,436	6,984	5,719	3,157	2,800	2,424	2,237	2,400
Inventory	-22.8%	1,406	1,821	2,656	3,426	3,334	4,912	5,493	5,893	5,373	5,538	5,813	5,334	5,877	5,876	5,189	4,218	3,484	3,405	3,951	4,309	4,493
Net PPE	2.5%	2,586	2,523	2,434	1,931	1,254	1,271	1,279	1,224	1,261	1,339	1,282	1,337	1,424	1,537	1,657	1,904	2,028	2,251	2,398	2,443	2,562
Goodwill	-100.0%	-	781	781	781	781	781	781	781	781	781	781	781	781	781	781	781	781	781	781	781	781
Liabilities	17.0%	14,816	12,658	14,981	14,739	16,063	15,827	15,818	16,997	17,255	16,605	14,534	13,161	14,990	13,987	14,023	13,799	14,298	12,960	10,032	9,351	7,880
Current Liabilities	32.3%	11,762	8,890	10,986	10,471	11,509	10,968	10,691	15,477	6,348	14,735	11,911	10,491	6,143	5,720	6,605	6,481	6,685	5,691	6,481	5,607	6,365
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	653	572	493	-	-	-	-	-	-	-	-
LT Debt, Current	-17.1%	378	456	404	423	962	1,000	1,000	1,000	813	733	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	653	572	493	-	-	-	-	-	-	-	-
Shareholder's Equity	-178.0%	-3,584	4,595	2,627	5,012	4,296	4,266	5,509	1,282	3,397	6,168	7,869	10,430	5,870	3,302	5,330	4,605	916	4,631	6,500	6,279	6,731
Retained Earnings	-2.5%	-284,168	-277,154	-273,539	-271,279	-266,193	-262,761	-259,521	-256,833	-264,662	-262,009	-260,235	-255,696	-253,283	-250,434	-247,971	-241,534	-236,932	-232,885	-230,603	-229,306	-227,435
Additional Paid-In Capital	0.3%	282,383	281,632	277,266	277,253	270,377	267,731	265,596	258,614	268,459	268,336	268,244	266,145	259,058	253,537	252,937	245,704	237,313	236,830	236,343	234,624	235,888
Accumulated Depreciation	-	7,575	-	-	-	7,175	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	15.3%	3,618	3,137	2,482	1,536	1,037	695	299	288	280	265	265	254	199	-	-	-	-	-	-	-	-
Minority Interest	-43.9%	-1,917	-1,332	-1,207	-1,069	-973	-833	-670	-557	-431	-199	-181	-48.00	70.00	170	316	389	530	687	778	956	-1,711
Float	-	-	-	2,828	-	-	-	4,278	-	-	-	26,985	-	-	-	27,692	-	-	-	4,733	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-713.9%	-2,043	-251	-812	-615	-1,182	-1,000	-942	-4,159	-326	-1,050	-1,292	-3,952	-2,534	-2,906	-6,412	-2,541	258	-607	-475	-2,436	448
Share Based Compensation	28.6%	9.00	7.00	13.00	10.00	83.00	70.00	72.00	42.00	111	92.00	2,099	258	265	234	314	67.00	155	253	125	81.00	177
Cashflow From Investing	-6.7%	-192	-180	-590	-771	-92.00	-89.00	-154	-65.00	-29.00	16.00	-53.00	-27.00	-	-	-	-23.00	-4.00	-36.00	-104	-38.00	-253
Cashflow From Financing	-	217	-	-	3,061	1,549	993	1,450	594	-	-	-	6,832	5,258	356	6,675	5,133	103	1,019	766	2,311	-16.00

THMO Income Statement

2023-09-30

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net revenues	$ 2,194,000	$ 2,115,000	$ 7,039,000	$ 7,807,000
Cost of revenues	1,799,000	1,678,000	5,070,000	5,491,000
Gross profit	395,000	437,000	1,969,000	2,316,000
Selling, general and administrative	1,686,000	1,982,000	5,346,000	5,665,000
Research and development	266,000	470,000	955,000	1,317,000
Total operating expenses	1,952,000	2,452,000	6,301,000	6,982,000
Loss from operations	(1,557,000)	(2,015,000)	(4,332,000)	(4,666,000)
Other expenses:
Interest expense	(2,118,000)	(1,391,000)	(6,689,000)	(3,572,000)
Loss on retirement of debt	(87,000)		(326,000)
Other income (expenses)	(22,000)	(3,000)	(27,000)	1,000
Total other expenses	(2,183,000)	(1,388,000)	(6,988,000)	(3,573,000)
Net loss	(3,740,000)	(3,403,000)	(11,320,000)	(8,239,000)
Loss attributable to noncontrolling interests	(125,000)	(163,000)	(359,000)	(402,000)
Net loss attributable to common stockholders	(3,615,000)	(3,240,000)	(10,961,000)	(7,837,000)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Net loss	(3,740,000)	(3,403,000)	(11,320,000)	(8,239,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	9,000	22,000	3,000	67,000
Comprehensive loss	(3,731,000)	(3,381,000)	(11,317,000)	(8,172,000)
Comprehensive loss attributable to noncontrolling interests	(125,000)	(163,000)	(359,000)	(402,000)
Comprehensive loss attributable to common stockholders	$ (3,606,000)	$ (3,218,000)	$ (10,958,000)	$ (7,770,000)
Earnings Per Share [Abstract]
Basic and diluted net loss per common share (in dollars per share)	$ (1.44)	$ (4.66)	$ (5.26)	$ (18.49)
Weighted average common shares outstanding basicand diluted (in shares)	2,503,631	694,795	2,083,095	423,897

THMO Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,018,000	$ 4,177,000
Accounts receivable, net of allowance for credit losses of $2,000 ($149,000 at December 31, 2022)	368,000	1,865,000
Inventories	1,821,000	3,334,000
Prepaid expenses and other current assets	718,000	1,508,000
Total current assets	6,925,000	10,884,000
Inventories, non-current	772,000	1,003,000
Equipment and leasehold improvements, net	2,523,000	1,254,000
Right-of-use operating lease assets, net	190,000	372,000
Goodwill	781,000	781,000
Intangible assets, net	1,262,000	1,286,000
Other assets	255,000	256,000
Total assets	15,921,000	19,386,000
Accounts payable	591,000	820,000
Accrued payroll and related expenses	451,000	399,000
Deferred revenue – short-term	818,000	782,000
Convertible promissory note – related party	4,817,000	5,777,000
Interest payable – related party	225,000	1,492,000
Convertible promissory note, net	456,000	962,000
Other current liabilities	1,532,000	1,277,000
Total current liabilities	8,890,000	11,509,000
Operating lease obligations – long-term		131,000
Deferred revenue – long-term	680,000	911,000
Other noncurrent liabilities	17,000	17,000
Total liabilities	12,658,000	16,063,000
Commitments and Contingencies
Common stock, $0.001 par value; 350,000,000 shares authorized; 3,136,504 issued and outstanding (1,037,138 at December 31, 2022)	3,000	1,000
Additional paid in capital	281,632,000	270,377,000
Accumulated deficit	(277,154,000)	(266,193,000)
Accumulated other comprehensive loss	114,000	111,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	4,595,000	4,296,000
Noncontrolling interests	(1,332,000)	(973,000)
Total equity	3,263,000	3,323,000
Total liabilities and equity	15,921,000	19,386,000
Lease Agreement with Z3 Investment LLC [Member]
Current assets:
Right-of-use operating lease assets, net	3,213,000	3,550,000
Operating lease obligations – long-term	$ 3,071,000	$ 3,495,000

About ThermoGenesis Holdings Inc

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.

CEO	Dr. Xiaochun Xu M.B.A., Ph.D.
WEBSITE	thermogenesis.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	40

ThermoGenesis Holdings Inc Frequently Asked Questions

What is the ticker symbol for ThermoGenesis Holdings Inc? What does THMO stand for in stocks?

THMO is the stock ticker symbol of ThermoGenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ThermoGenesis Holdings Inc (THMO)?

As of Tue Apr 16 2024, market cap of ThermoGenesis Holdings Inc is 2.2 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of THMO stock?

You can check THMO's fair value in chart for subscribers.

What is the fair value of THMO stock?

You can check THMO's fair value in chart for subscribers. The fair value of ThermoGenesis Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ThermoGenesis Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for THMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ThermoGenesis Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether THMO is over valued or under valued. Whether ThermoGenesis Holdings Inc is cheap or expensive depends on the assumptions which impact ThermoGenesis Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for THMO.

What is ThermoGenesis Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, THMO's PE ratio (Price to Earnings) is -0.15 and Price to Sales (PS) ratio is 0.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. THMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ThermoGenesis Holdings Inc's stock?

In the past 10 years, ThermoGenesis Holdings Inc has provided -0.627 (multiply by 100 for percentage) rate of return.